Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study

de, María Montes; Varela, María Victorina López; Menezes, Ana Maria Baptista; Wehrmeister, Fernando César; Ramirez, Larissa; Miravitlles, Marc

doi:10.36416/1806-3756/e20210156

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total CAT score was calculated for each individual by summing the points for each CAT variable, ranging from 0 to 40. mMRC respiratory validated questionnaire has a 5-point scoring range (0-4) based on the severity of dyspnea. [17] The study was approved by the Clinical Research Ethics Committee of the First A liated Hospital, Collage of Medicine, Zhejiang university. All the study participants were aware of the study's purpose, risks, and bene ts, gave informed consent and signed written consent forms.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Decreased serum IL-35 and IL-37 in COPD patients with severe emphysema

Yang,

Wei,

Yan

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease(COPD) is a heterogeneous syndrome and chronic persistent inflammation has been discovered to play critical role in the structural damage leading to the progression of emphysema. IL-35 and IL-37 are both immune-suppressing cytokines which exert inhibitory effects on a lot of inflammatory disorders. This study aimed to determine the correlation between serum levels of IL-35 and IL-37 with the severity of emphysema and clinical parameters of COPD patients. Methods We detected the serum levels of IL-35, IL-37 and IL-33 from 64 Chinese patients with stable COPD by using an enzyme-linked immunosorbent assay and examined the association of their concentrations with COPD patients’ clinical parameters. Results The serum levels of IL-35 and IL-37 were significantly decreased in the COPD patients with severe emphysema subtype compared to non-emphysema or mild-to-moderate emphysema subtype. The serum level of IL-35 was correlated with body mass index(BMI), modified Medical Research Council(mMRC) score and the concentrations of IL-33 and IL-37. The lower IL-35 group exhibited decreased BMI, lower FEV1/FVC, severe extent of emphysema and worse mMRC. Multivariable regression showed that lower FEV1/FVC, worse mMRC score and decreased serum levels of IL-35 were independently associated with severe emphysema. Conclusions We found that the serum IL-35 and IL-37 levels were decreased in severe emphysema subtype. The lower level of IL-35 was correlated with lower BMI and worse mMRC score. IL-35 concentrations, FEV1/FVC and mMRC score were independently associated with the extent of emphysema.

show abstract

Section: Study Design and Participantsmentioning

confidence: 99%

Decreased serum IL-35 and IL-37 in COPD patients with severe emphysema

Yang,

Wei,

Yan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Modulating asthma–COPD overlap responses with IL-17 inhibition

Camargo,

Righetti,

de Almeida

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundIL-17 is a modulator of the inflammatory response and is implicated in lung remodeling in both asthma and chronic obstructive pulmonary disease (COPD). Well as and probably in patients with asthma–COPD overlap (ACO).MethodsIn this study, we evaluated the response of the airways and alveolar septa to anti-IL-17 treatment in an ACO model. Fifty-six male BALB/c mice were sensitized with ovalbumin (OVA group), received porcine pancreatic elastase (PPE group), or both (ACO group). Mice were then treated with either anti-IL-17 monoclonal antibody or saline. We evaluated hyperresponsiveness, bronchoalveolar lavage fluid (BALF) cell counts, and mean alveolar diameter. We quantified inflammatory, response, extracellular matrix remodeling, oxidative stress markers, and signaling pathway markers.ResultsAnti-IL-17 treatment in the ACO anti-IL-17 group reduced the maximum response of respiratory system Rrs, Ers, Raw, Gtis, this when compared to the ACO group (p<0.05). There was a reduction in the total number of inflammatory cells, neutrophils, and macrophages in the BALF in the ACO anti-IL-17 group compared to the ACO group (p<0.05). There was attenuated dendritic cells, CD4+, CD8+, FOXP3, IL-1β, IL-2, IL-6, IL-13, IL-17, IL-33 in ACO anti-IL-17 group in airway and alveolar septum compared to the ACO group (p<0.05). We observed a reduction of MMP-9, MMP-12, TIMP-1, TGF-β, collagen type I in ACO anti-IL-17 group in airway and alveolar septum compared to the ACO group (p < 0.05). We also observed a reduction of iNOS and 8-iso-PGF2α in the airways and in the alveolar septum was reduced in the ACO anti-IL-17group compared to the ACO group (p < 0.05). Regarding the signaling pathways, NF-kB, ROCK-1, and ROCK-2 in the airway and alveolar septum were attenuated in the ACO anti-IL-17 group when compared to the ACO group (p<0.05).ConclusionsOur results suggest that inhibiting IL-17 modulates cell-associated cytokine production in lung tissue, extracellular matrix remodeling, and oxidative stress in ACO through the modulation of NF-kB and FOXP3.

show abstract

A shadow in the GOLD ABCD classification system: measurement of perception of symptoms in COPD

Crisafulli

Sartori

2021

J Bras Pneumol.

View full text Add to dashboard Cite

Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study

Cited by 3 publications

References 40 publications

Decreased serum IL-35 and IL-37 in COPD patients with severe emphysema

Decreased serum IL-35 and IL-37 in COPD patients with severe emphysema

Modulating asthma–COPD overlap responses with IL-17 inhibition

A shadow in the GOLD ABCD classification system: measurement of perception of symptoms in COPD

Contact Info

Product

Resources

About